Zepbound (tirzepatide) causes approximately 22.5% weight loss versus approximately 15% for Wegovy (semaglutide) in clinical trials. Both are FDA-approved for weight loss. Zepbound shows superior efficacy in head-to-head comparison, but Wegovy has a longer track record and better insurance coverage in some plans. The best choice depends on your individual health profile and insurance access.
The Fundamentals: How They Differ
Understanding the mechanistic difference is key to understanding the clinical results.
| Core Mechanism | |
|---|---|
| Wegovy (Semaglutide) | GLP-1 receptor agonist (single target) |
| Zepbound (Tirzepatide) | Dual GIP/GLP-1 receptor agonist (dual target) |
What does this mean? Wegovy activates only the GLP-1 receptor, which suppresses appetite and slows gastric emptying. Zepbound activates both the GLP-1 receptor and the GIP receptor (Glucose-dependent Insulinotropic Polypeptide), a second appetite-regulating hormone. This dual action produces a compounded effect on hunger suppression, satiety, and energy expenditure — which translates to greater weight loss in clinical studies.
FDA Approvals for Weight Loss:
- Wegovy (Semaglutide): FDA approved for weight loss in June 2021; originally approved for type 2 diabetes as Ozempic in 2017
- Zepbound (Tirzepatide): FDA approved for weight loss in November 2023; originally approved for type 2 diabetes as Mounjaro in 2022
Weight Loss: Clinical Trial Data
The most compelling evidence comes from the SURMOUNT and STEP trial series. The SURMOUNT-5 trial directly compared these medications head-to-head:
Average Weight Loss Results (FDA-Approved Indications)
In absolute terms, if a 200-pound person took Wegovy, they'd lose roughly 30 pounds. On Zepbound, they'd lose roughly 45 pounds on average. These are median figures; individual results vary significantly based on genetics, adherence, diet, and exercise.
These trials enrolled people with obesity and no prior GLP-1 experience, in controlled settings with dietary support and follow-up. Real-world results may vary. Additionally, weight loss typically plateaus after 1-2 years; these figures represent peak loss during the trial period.
Side Effects: Which Causes More Nausea?
Both medications cause similar gastrointestinal side effects, but frequency and severity differ slightly between users.
| Side Effect | Wegovy (Semaglutide) | Zepbound (Tirzepatide) |
|---|---|---|
| Nausea | 30–50% of users | 25–40% of users (reported as slightly less frequent but more intense) |
| Vomiting | 10–20% | 10–15% |
| Constipation | 20–30% | 20–25% |
| Diarrhea | 25–35% | 20–30% |
| Abdominal pain | 15–25% | 20–30% |
| Pancreatitis (rare) | <0.1% | <0.1% |
Medical Disclaimer: These medications carry black-box warnings for thyroid cancer risk (based on rodent studies, not human evidence) and are contraindicated in personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Both require monitoring for gastroparesis and acute kidney injury, especially with vomiting. Discuss contraindications with your healthcare provider before starting either medication.
Cost Comparison
Pricing is complex and depends heavily on insurance and prescription source. Both are weight loss medications and typically not covered by insurance.
| Wegovy (Semaglutide) | Zepbound (Tirzepatide) | |
|---|---|---|
| List Price | ~$1,349/month | ~$1,060/month |
| With Insurance (Diabetes Only) | $0–$400/month (copay varies) | $0–$400/month (copay varies) |
| For Weight Loss Only | $200–$500/month (typically not covered) | $200–$500/month (typically not covered) |
| Manufacturer Coupons | Novo Nordisk coupon: savings up to $500/month | Eli Lilly coupon: savings up to $500/month |
| Compounded (pharmacy-made) | $100–$300/month (unregulated; FDA action pending) | $100–$300/month (unregulated; FDA action pending) |
Key insight: Zepbound has a lower list price than Wegovy. However, if you have type 2 diabetes, either medication is likely covered by insurance at a reasonable copay. If you're using it for weight loss alone, insurance rarely covers either, and manufacturer coupons or patient assistance programs become critical to affordability.
Availability and Supply Status (2026)
Both medications experienced supply shortages in 2023–2024 due to high demand. Current status as of March 2026:
Supply has normalized as of early 2026. Generally available at most major pharmacies, though demand remains high. Compounded versions are being phased out by FDA action.
Supply constraints easing but still variable by region. Eli Lilly is expanding manufacturing capacity. Availability improving steadily throughout 2026.
Check with your pharmacy before deciding based on availability alone — both should be obtainable in most U.S. markets by mid-2026, though supply can vary by region and prescription source.
Which Is Right for You? A Decision Framework
Choose Zepbound (Tirzepatide) if:
- Maximum weight loss is your primary goal, and you tolerate GI side effects reasonably well
- You've tried Wegovy and plateaued or had inadequate weight loss response
- You want the newest FDA-approved option with the strongest clinical efficacy data
- You have good insurance coverage or access to manufacturer coupons for lower cost
- You prefer the lower list price compared to Wegovy
- You value the dual GIP/GLP-1 mechanism for enhanced appetite suppression
Choose Wegovy (Semaglutide) if:
- You value a longer track record of safety data (available since 2021 for weight loss, 2017 for diabetes)
- You're concerned about GI side effects and want a slightly gentler option
- Insurance covers semaglutide more favorably in your specific plan
- Availability or supply is a limiting factor in your area
- You're in a telehealth program that specializes in semaglutide dosing protocols
- You've had good results with Ozempic (also semaglutide) and want to stay with the same mechanism
Both medications require lifestyle change — diet, movement, and behavior modification — to sustain results long-term. Medication is a tool, not a complete solution. Weight regain after stopping is common with both drugs if eating and activity patterns don't change.
Can You Switch Between Them?
Yes. Switching from Wegovy to Zepbound (or vice versa) is medically feasible and sometimes recommended. Common reasons to switch:
- Inadequate weight loss: If you're not losing enough on Wegovy, your doctor may trial Zepbound
- Intolerable side effects: Some people tolerate one better than the other. Individual chemistry varies
- Insurance coverage changes: If your plan suddenly won't cover one, switching may become necessary
- Supply issues: Temporary access problems might force a switch
- Cost considerations: If one becomes significantly more affordable through new coupons or coverage
How to switch safely: Don't attempt self-directed switching. Your doctor will typically:
- Discontinue the first medication
- Wait 1–2 weeks (allows your system to clear the prior drug)
- Start the new medication at a low dose (e.g., 2.5mg for tirzepatide or 0.25mg for semaglutide)
- Titrate up gradually over weeks to reach therapeutic dose
Direct equivalent dosing between the two is not straightforward because their mechanisms differ. Your doctor will adjust doses based on your response and tolerance.
Evidence for Cardiovascular and Metabolic Benefits
Semaglutide (Wegovy)
The SUSTAIN-6 trial showed semaglutide reduces major adverse cardiovascular events (MACE) in people with type 2 diabetes by 26%. The SELECT trial (2023) demonstrated cardiovascular benefit even in non-diabetic populations with obesity and established cardiovascular disease.
Tirzepatide (Zepbound)
The SURMOUNT-CV trial is currently examining cardiovascular outcomes in non-diabetic populations with obesity. Preliminary data suggests potential CV benefit, but long-term safety data is still accumulating since Zepbound's weight loss approval is more recent (2023).
Neither medication is a substitute for treatment of high blood pressure, high cholesterol, or other cardiovascular risk factors. Both should be used as adjunctive therapy alongside evidence-based cardiovascular care.
Frequently Asked Questions
Can I use these medications if I have type 2 diabetes?
Yes. Wegovy (semaglutide) is prescribed off-label for diabetes as Ozempic; Zepbound (tirzepatide) is prescribed as Mounjaro for diabetes. When used for diabetes, insurance coverage is generally better than for weight loss alone. Discuss with your doctor which is better for your specific diabetes management goals.
Do you need to take these medications forever?
Not necessarily, but weight regain is common after stopping. Clinical studies show approximately 50% weight regain within 1 year of discontinuation if diet and exercise don't improve. Some people use them long-term; others cycle on and off. Discuss long-term strategy with your provider.
What happens if I miss a dose?
Both medications are weekly injectables. If you miss a weekly dose, inject as soon as you remember (unless it's within 2 days of your next scheduled dose). Don't double-dose. Consistency matters for optimal appetite suppression.
Can I use these if I have Type 1 Diabetes?
Neither Wegovy nor Zepbound is approved for type 1 diabetes. They are approved only for type 2 diabetes or obesity without diabetes. Use in type 1 is off-label and carries increased risk of diabetic ketoacidosis. Do not use without explicit physician approval and close monitoring.
Which medication is better for PCOS (Polycystic Ovary Syndrome)?
Both have shown benefit in PCOS because they improve insulin sensitivity and reduce androgen levels. Zepbound (tirzepatide) may have a slight edge due to its dual-agonist mechanism and superior insulin action, but evidence in PCOS specifically is still emerging. Discuss with your endocrinologist or gynecologist.
How quickly will I see weight loss results?
Most people begin seeing measurable weight loss within 4-6 weeks of starting either medication, though initial weight loss may be modest. Significant results typically become apparent after 2-3 months as doses are titrated upward. Peak weight loss occurs around 6-12 months of consistent use.
This article is for educational purposes and should not be construed as medical advice. Consult a licensed healthcare provider before starting, stopping, or switching GLP-1 medications. Individual health profiles, contraindications, and drug interactions vary. All medication decisions should be made collaboratively with your doctor.
Takeaway
Zepbound (tirzepatide) is the more potent medication for weight loss based on available clinical trials, producing approximately 47% more weight loss than Wegovy in head-to-head comparison. However, Wegovy (semaglutide) has a longer safety track record, better insurance coverage in many plans, and excellent efficacy for most patients. The best choice depends on your specific health situation, insurance access, side effect tolerance, cost considerations, and your provider's experience.
Both medications are significantly more effective than older GLP-1 options and genuinely help people lose weight and improve metabolic health. The gap between them is real but often narrower than the gap between either of them and no medication at all.
Next steps: See our full comparison of all GLP-1 medications, or take our quiz to find programs that prescribe either Zepbound or Wegovy.